Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
The Lymphoma Academic Research Organisation
CellCentric Ltd.
Incyte Corporation
M.D. Anderson Cancer Center
Sumitomo Pharma America, Inc.
University of Chicago
Ruijin Hospital
University of Virginia
M.D. Anderson Cancer Center
Weill Medical College of Cornell University
M.D. Anderson Cancer Center